Virtue Capital Management LLC acquired a new stake in shares of Novartis AG (NYSE:NVS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,256 shares of the company’s stock, valued at approximately $189,000.
A number of other large investors have also bought and sold shares of the stock. Capital Bank & Trust Co lifted its stake in Novartis by 5.5% during the third quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock worth $11,865,000 after purchasing an additional 7,201 shares during the last quarter. Atlantic Trust Group LLC lifted its stake in Novartis by 54.2% during the third quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock worth $6,218,000 after purchasing an additional 25,452 shares during the last quarter. Rothschild Investment Corp IL lifted its stake in Novartis by 26.9% during the fourth quarter. Rothschild Investment Corp IL now owns 26,200 shares of the company’s stock worth $2,200,000 after purchasing an additional 5,550 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in Novartis during the third quarter worth about $1,245,000. Finally, Cedar Hill Associates LLC bought a new stake in Novartis during the third quarter worth about $248,000. 10.80% of the stock is owned by institutional investors.
Shares of Novartis AG (NYSE NVS) opened at $82.80 on Monday. Novartis AG has a 52 week low of $72.67 and a 52 week high of $94.19. The company has a quick ratio of 0.91, a current ratio of 1.21 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $191,792.67, a PE ratio of 25.46, a PEG ratio of 1.92 and a beta of 0.78.
Several brokerages have issued reports on NVS. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a research note on Thursday, January 18th. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Zacks Investment Research lowered Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a research note on Tuesday, January 2nd. Finally, Bank of America lowered Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, December 6th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company. Novartis has an average rating of “Hold” and an average target price of $87.51.
ILLEGAL ACTIVITY NOTICE: “2,256 Shares in Novartis AG (NVS) Acquired by Virtue Capital Management LLC” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.themarketsdaily.com/2018/03/12/2256-shares-in-novartis-ag-nvs-acquired-by-virtue-capital-management-llc.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.